London-based Big Picture Bio emerges from stealth with €2.55 million to develop AI-designed cancer drug combinations
Big Picture Bio, a London-based BioTech startup developing AI-designed combination therapies for cancer and other complex diseases, has emerged from stealth with a combined funding round of €2.55 million (£2.2 million). The funding comprises a €1.75 million (£1.5 million) pre-Seed round co-led by Kadmos Capital and Exceptional Ventures, alongside €815k (£700k) in non-dilutive support from […] The…
London-based bio-tech startup Big Picture Bio has emerged from stealth mode with €2.55 million ($2.2 million) in funding to develop AI-designed combination therapies for cancer and other complex diseases. The financing, comprising a €1.75 million ($1.5 million) pre-Seed round led by Kadmos Capital and Exceptional Ventures, alongside €815k (£700k) in non-dilutive support from Innovate UK, marks the company's first step in transforming its AI-driven predictions into laboratory-tested therapies.
Dr Kerstin Papenfuss, CEO and co-founder, emphasized that cancer is not a single disease with a single target, but a dynamic systems that requires combination therapies. The company's predictive models have already demonstrated their efficacy, as they accurately forecasted the failure of Regeneron's fianlimab clinical trial and accurately predicted 12 out of 14 drug combinations ahead of the 2026 ASCO oncology conference.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
